|
1
|
Isaji S, Mizuno S, Windsor JA, Bassi C,
Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW,
Kishiwada M, et al: International consensus on definition and
criteria of borderline resectable pancreatic ductal adenocarcinoma
2017. Pancreatology. 18:2–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee B, Yoon YS, Kang M, Park Y, Lee E, Jo
Y, Lee JS, Lee HW, Cho JY and Han HS: Validation of the anatomical
and biological definitions of borderline resectable pancreatic
cancer according to the 2017 International consensus for survival
and recurrence in patients with pancreatic ductal adenocarcinoma
undergoing upfront surgery. Ann Surg Oncol. 30:3444–3454. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong
Y, Qian Y, Huang Q, Ni Q, Liu C and Yu X: Roles of CA19-9 in
pancreatic cancer: Biomarker, predictor and promoter. Biochim
Biophys Acta Rev Cancer. 1875:1884092021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng H, Luo G, Lu Y, Jin K, Guo M, Xu J,
Long J, Liu L, Yu X and Liu C: The combination of systemic
inflammation-based marker NLR and circulating regulatory T cells
predicts the prognosis of resectable pancreatic cancer patients.
Pancreatology. 16:1080–1084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Szkandera J, Stotz M, Absenger G,
Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi
W, Lackner C, Ress AL, et al: Validation of C-reactive protein
levels as a prognostic indicator for survival in a large cohort of
pancreatic cancer patients. Br J Cancer. 110:183–188. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and
Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio
in pancreatic cancer: A meta-analysis. World J Gastroenterol.
21:2807–2815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takahashi H, Yamada D, Asukai K, Wada H,
Hasegawa S, Hara H, Shinno N, Ushigome H, Haraguchi N, Sugimura K,
et al: Clinical implications of the serum CA19-9 level in
‘biological borderline resectability’ and ‘biological downstaging’
in the setting of preoperative chemoradiation therapy for
pancreatic cancer. Pancreatology. 20:919–928. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barugola G, Partelli S, Marcucci S,
Sartori N, Capelli P, Bassi C, Pederzoli P and Falconi M:
Resectable pancreatic cancer: Who really benefits from resection?
Ann Surg Oncol. 16:3316–3322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gemenetzis G, Groot VP, Blair AB, Ding D,
Thakker SS, Fishman EK, Cameron JL, Makary MA, Weiss MJ, Wolfgang
CL and He J: Incidence and risk factors for abdominal occult
metastatic disease in patients with pancreatic adenocarcinoma. J
Surg Oncol. 118:1277–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Groot VP, Gemenetzis G, Blair AB,
Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar
IQ, Cameron JL, et al: Defining and predicting early recurrence in
957 patients with resected pancreatic ductal adenocarcinoma. Ann
Surg. 269:1154–1162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitsunaga S, Ikeda M, Shimizu S, Ohno I,
Takahashi H, Okuyama H, Ueno H, Morizane C, Kondo S, Sakamoto Y, et
al: C-reactive protein level is an indicator of the aggressiveness
of advanced pancreatic cancer. Pancreas. 45:110–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Black S, Kushner I and Samols D:
C-reactive protein. J Biol Chem. 279:48487–48490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McMillan DC, Canna K and McArdle CS:
Systemic inflammatory response predicts survival following curative
resection of colorectal cancer. Br J Surg. 90:215–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miki C, Konishi N, Ojima E, Hatada T,
Inoue Y and Kusunoki M: C-reactive protein as a prognostic variable
that reflects uncontrolled up-regulation of the IL-1-IL-6 network
system in colorectal carcinoma. Dig Dis Sci. 49:970–976. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawata A, Une Y, Hosokawa M, Uchino J and
Kobayashi H: Tumor-infiltrating lymphocytes and prognosis of
hepatocellular carcinoma. Jpn J Clin Oncol. 22:256–263.
1992.PubMed/NCBI
|
|
18
|
Yamashita J, Ogawa M and Shirakusa T:
Free-form neutrophil elastase is an independent marker predicting
recurrence in primary breast cancer. J Leukoc Biol. 57:375–378.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nurmi AM, Mustonen H, Haglund C and
Seppänen H: Changes in CRP and CA19-9 during preoperative
oncological therapy predict postoperative survival in pancreatic
ductal adenocarcinoma. Oncology. 99:686–698. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakamoto T, Saito H, Uchinaka E, Morimoto
M, Amisaki M, Tokuyasu N, Honjo S, Ashida K and Fujiwara Y: The
Combination of neutrophil-to-lymphocyte ratio and serum
carbohydrate antigen 19-9 level as a prognostic indicator in
patients with recurrent pancreatic cancer. Anticancer Res.
38:5497–5503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asaoka T, Miyamoto A, Maeda S, Tsujie M,
Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, et
al: Prognostic impact of preoperative NLR and CA19-9 in pancreatic
cancer. Pancreatology. 16:434–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schlick K, Magnes T, Huemer F, Ratzinger
L, Weiss L, Pichler M, Melchardt T, Greil R and Egle A: C-reactive
protein and neutrophil/lymphocytes ratio: prognostic indicator for
doubling overall survival prediction in pancreatic cancer patients.
J Clin Med. 8:17912019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stevens L, Pathak S, Nunes QM,
Pandanaboyana S, Macutkiewicz C, Smart N and Smith AM: Prognostic
significance of pre-operative C-reactive protein and the
neutrophil-lymphocyte ratio in resectable pancreatic cancer: A
systematic review. HPB (Oxford). 17:285–291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y,
Yang C, Fan K, Huang Q, Long J, et al: New observations on the
utility of CA19-9 as a biomarker in Lewis negative patients with
pancreatic cancer. Pancreatology. 18:971–976. 2018. View Article : Google Scholar : PubMed/NCBI
|
